<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11906762</article-id><article-id pub-id-type="pmcid-ver">PMC11906762.1</article-id><article-id pub-id-type="pmcaid">11906762</article-id><article-id pub-id-type="pmcaiid">11906762</article-id><article-id pub-id-type="pmid">40082516</article-id><article-id pub-id-type="doi">10.1038/s41598-025-93425-3</article-id><article-id pub-id-type="publisher-id">93425</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Toward a high-throughput in vitro model for estimating vitreous humor permeability of topically applied drugs</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Vincze</surname><given-names initials="A">Anna</given-names></name><address><email>vincze.anna@semmelweis.hu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simon</surname><given-names initials="E">Eszter</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kopl&#225;nyi</surname><given-names initials="G">G&#225;bor</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stankovits</surname><given-names initials="JG">J&#243;zsef Gergely</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balogh-Weiser</surname><given-names initials="D">Di&#225;na</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gyarmati</surname><given-names initials="B">Benj&#225;min</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nagy</surname><given-names initials="ZZ">Zolt&#225;n Zsolt</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Balogh</surname><given-names initials="GT">Gy&#246;rgy T.</given-names></name><address><email>balogh.gyorgy.tibor@semmelweis.hu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01g9ty582</institution-id><institution-id institution-id-type="GRID">grid.11804.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0942 9821</institution-id><institution>Department of Pharmaceutical Chemistry, </institution><institution>Semmelweis University, </institution></institution-wrap>H&#337;gyes Endre Street 9, Budapest, H-1092 Hungary </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01g9ty582</institution-id><institution-id institution-id-type="GRID">grid.11804.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0942 9821</institution-id><institution>Center for Pharmacology and Drug Research &amp; Development, </institution><institution>Semmelweis University, </institution></institution-wrap>&#220;ll&#337;i Street 26, Budapest, H-1092 Hungary </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02w42ss30</institution-id><institution-id institution-id-type="GRID">grid.6759.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 0451</institution-id><institution>Department of Electronics Technology, Faculty of Electrical Engineering and Informatics, </institution><institution>Budapest University of Technology and Economics, </institution></institution-wrap>M&#369;egyetem Quay 3, Budapest, H-1111 Hungary </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02w42ss30</institution-id><institution-id institution-id-type="GRID">grid.6759.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 0451</institution-id><institution>Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, </institution><institution>Budapest University of Technology and Economics, </institution></institution-wrap>M&#369;egyetem Quay 3, Budapest, H-1111 Hungary </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02w42ss30</institution-id><institution-id institution-id-type="GRID">grid.6759.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 0451</institution-id><institution>Department of Physical Chemistry and Materials Science, Faculty of Chemical Technology and Biotechnology, </institution><institution>Budapest University of Technology and Economics, </institution></institution-wrap>M&#369;egyetem Quay 3, Budapest, H-1111 Hungary </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01g9ty582</institution-id><institution-id institution-id-type="GRID">grid.11804.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0942 9821</institution-id><institution>Department of Ophthalmology, </institution><institution>Semmelweis University, </institution></institution-wrap>M&#225;ria Street 39, Budapest, H-1085 Hungary </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>8768</elocation-id><history><date date-type="received"><day>12</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>14</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-15 10:26:04.270"><day>15</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_93425.pdf"/><abstract id="Abs1"><p id="Par1">The vitreous humor of the eye presents a crucial target for posterior segment therapy due to its proximity to the retina and relatively easy accessibility. Although intravitreous injections have long been the primary method for treating posterior segment disorders, recent successes in non-invasive topical treatments have led to the exploration of alternative administration routes. The objective of our study is to establish a platform for a Parallel Artificial Membrane Permeability Assay (PAMPA) model that mimics the posterior segment, modelling the permeation process of compounds applied topically on the eye. The study demonstrates the acceptor-phase effects of sodium hyaluronate and agar on passive permeability, while applying a previously published vitreous humor-mimetic material. Physicochemical similarities of the acceptor phase media and freshly excised porcine vitreous humor further support the applicability of the mimetic material, based on viscosity and zeta potential measurement. As a result, a new concept is introduced for measuring posterior segment permeability, with potential for future high throughput screening applications.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-93425-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Posterior segment of the eye</kwd><kwd>Ocular permeability</kwd><kwd>In vitro permeability model</kwd><kwd>PAMPA</kwd><kwd>Vitreous humor</kwd><kwd>Vitreous substitutes</kwd><kwd>Sodium hyaluronate</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Medical research</kwd><kwd>Drug development</kwd><kwd>Preclinical research</kwd><kwd>Drug discovery</kwd><kwd>Drug delivery</kwd><kwd>Drug screening</kwd></kwd-group><funding-group><award-group><funding-source><institution>Semmelweis University</institution></funding-source></award-group><open-access><p>Open access funding provided by Semmelweis University.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par15">Ophthalmic diseases related to the posterior segment of the eye (age-related macular degeneration, proliferative vitreoretinopathy, diabetic macular oedema, endophthalmitis) are the leading causes of vision loss worldwide, however the therapeutic treatment of the posterior still poses a great challenge<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Target tissues include the vitreous body, the retina, and the choroid &#8211; and while there are more strategies to reach these tissues, none of them comes without drawbacks. The vitreous body is a&#8201;~&#8201;4&#160;g weighting, gel-like tissue filling the cavity between the lens and the retina, mainly consisting of water (99.9%), ions, hyaluronic acid and collagen<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Invasive therapies (mainly intravitreal injections) show the highest success rate with the lowest systemic absorption, although they often cause retinal detachment, elevated intraocular pressure, glaucoma, choroidal or vitreous haemorrhage or lead to cataract formation<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Another problem is the lack of patient compliance, as these therapies are not only invasive and thus uncomfortable, but they also require repeated administration by trained personnel<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Some intravitreal inserts offer prolonged drug delivery, but their placement into the eye is still invasive (via injection or surgery) and the non-biodegradable ones require removal at some point<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. A further alternative is systemic administration, as drugs can enter the eye via the choroid from the blood circulation, however the blood-retina-barrier, and the efflux pumps of the retinal pigmented epithelium greatly limit the amount of drug reaching the posterior segment, thus higher doses are required with the increased risk of systemic adverse effects<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par16">The most convenient route would be topical administration offering better patient compliance and fewer side effects. In contrast with the onetime beliefs, nowadays it seems that eye drops can actually achieve therapeutic drug levels in the posterior segment (it was proved for aqueous eye drops containing dorzolamide<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, brimonidine<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, betaxolol<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, netarsudil<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, memantine<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>). Also, more and more unconventional eye drops have been demonstrated to be beneficial in the treatment of posterior segment disorders (e.g. liposomes, solid lipid nanocarriers, lipid DNA-nanoparticles, cyclodextrin-nanoparticles, chitosan oligosaccharide nanomicelles and chitosan-coated liposomes to deliver bevacizumab<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, indomethacin<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, brimonidine<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> dexamethasone<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> and triamcinolone acetonide<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> respectively).</p><p id="Par17">Only, the exact route to reach the posterior segment following topical administration is extremely complex, featuring plenty of static/dynamic barriers making it difficult to model the whole progress or to estimate the amount of drug reaching posterior tissues. Drug levels after topical administration in the vitreous and retina-choroid has been studied by in vivo and ex vivo methods. In vivo methods are expensive and unethical, as they include &#8216;simple&#8217; pharmacokinetic studies requiring the execution of the animals for each time point or vitreous dialysis involving surgical placement of a probe into the rabbit&#8217;s eye and eventually, execution of the animal after the experiments<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref></sup>. In the survey of <italic toggle="yes">Maurice et al.</italic> these methods are criticized because tissue contamination can occur during enucleation due to eye drop residues on the lid margins and eyelashes, meanwhile drug redistribution after death may also be an issue<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Ex vivo methods usually include arterial perfusion of the mammalian eye<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> or monitoring the distribution of a fluorescent compound by optical coherence tomography<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The main issue is that all in vivo and ex vivo studies are either purely methodological or focus solely on a single drug substance, resulting in limited data on the posterior segment permeability of a few drugs following topical administration. In vitro methods could be cost-effective, high-throughput and robust, but to the present, in vitro studies focus exclusively on intravitreal injections, investigating the diffusion of drugs in various polymer hydrogels mimicking the vitreous humor<sup><xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par18">This study aims to develop a permeability model utilising the PAMPA (Parallel Artificial Membrane Permeability Assay) method to evaluate posterior segment permeability followed by topical administration. Modification of the corneal-PAMPA model (focusing on the corneal permeability process) by altering the acceptor phase to mimic the vitreous body hopefully allows us to model the permeability process starting from the eye surface targeting the vitreous humor. Due to the involvement of many tissues including cornea, conjunctiva, sclera, iris, lens, vitreous, and choroid in the entire process, no precise permeation route is reported. The study includes the investigation of a vitreous humor-mimetic material as acceptor-side medium validated by <italic toggle="yes">Thakur et al.</italic> for in vitro drug and particle migration, and physicochemical similarities with porcine vitreous humor are demonstrated by rheological characterization and zeta potential measurement.</p></sec><sec id="Sec2"><title>Experimental</title><sec id="Sec3"><title>Materials</title><p id="Par19">The active pharmaceutical ingredients such as antipyrine, benzocaine, buspirone hydrochloride, carbamazepine, cetirizine dihydrochloride, chloroquine diphosphate, desipramine hydrochloride, dexamethasone, diclofenac Na, diltiazem hydrochloride, duloxetine hydrochloride, flurbiprofen, enoxacin, hydrocortisone, ketorolac, lornoxicam, methapyrilene, moxifloxacin hydrochloride, nepafenac, norfloxacin, ofloxacin, oxybuprocaine hydrochloride, piroxicam, prednisolone, propamidine, propranolol hydrochloride, pyrilamine, ranitidine hydrochloride, tenoxicam, tetracaine hydrochloride, timolol maleate and other chemicals like phosphate buffered saline (PBS) powder, L-&#945;-phosphatidylcholine (PC) were purchased from Merck KGaA (Darmstadt, Germany). Analytical grade solvents such as dimethyl sulfoxide (DMSO), acetonitrile, methanol, chloroform, n-hexane, dodecane were purchased also from Merck KGaA. Hyaluronic acid sodium salt (Na-HA) with different molecular weights: 200&#160;kDa (HA-200) and 855&#160;kDa (HA-855) was accessible from Medicinal Chemistry Laboratory II, Gedeon Richter Plc, (Gy&#246;mr&#337;i Street 19&#8211;21, 1107 Budapest, Hungary) with Erika Forrai&#8217;s assistance. Agar powder was purchased from VWR International Ltd. (Radnor, Pennsylvania, USA). In all experiments, distilled water was purified by the Millipore Milli-Q<sup>&#174;</sup> 140 Gradient Water Purification System. To gain freshly excised vitreous humor, porcine eyes were obtained from a local slaughterhouse (Porci&#243;-&#201;K Ltd., Albertirsa, Hungary).</p></sec><sec id="Sec4"><title>Preparation of hyaluronate and agar-based solutions</title><p id="Par20">To prepare HA/agar solutions the exact amount of HA and/or agar powder was weighted, added into boiling PBS (pH 7.4) and completely dissolved by vigorous stirring for 15&#160;min. Finally, the solutions were stored at room temperature overnight.</p></sec><sec id="Sec5"><title>In vitro permeability measurements (PAMPA)</title><p id="Par21">For the parallel artificial membrane permeability assay (PAMPA) previously published method of corneal-PAMPA was modified in some parameters<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. First, the active pharmaceutical ingredients (APIs) were dissolved in PBS buffer (pH 7.4) to make solutions of 250 &#181;M nominal concentration, except for two drugs: carbamazepine and dexamethasone, which were used in 100 &#181;M nominal concentration because of their poor solubility. Before each assay the PBS stock solutions were homogenized by using a Boeco Vortex Mixer V1 plus for 10&#8211;12&#160;s and an ultrasonic bath (VWR Ultrasonic Cleaner) for 10&#160;min. After that, phosphatidylcholine (PC, 16&#160;mg) was dissolved in a solvent mixture (600 &#181;L) of 70% (v/v) hexane, 25% (v/v) dodecane, 5% (v/v) chloroform at 0&#160;&#176;C using an ultrasonic bath. Then 5 &#181;L of the lipid solution was pipetted into each well of donor plate (MultiscreenTM-IP, MAIPN4510, pore size 0.45&#160;mm; Millipore), creating an artificial membrane of PC/dodecane solution on the porous bottom of the wells as hexane and chloroform evaporated. Then the donor plate was fit into the acceptor plate (Multiscreen Acceptor Plate, MSSACCEPTOR; Millipore), already containing 300 &#181;L acceptor phase solution (PBS or polymer solution). Finally, 150 &#181;L of the API solutions were put on the membrane of the donor plate. For each assay 3 replicates per compounds were measured. The sandwich plate was covered with a sheet of wet paper tissue and a plate lid to avoid evaporation of the solvent. The plates were incubated for 4&#160;h at 35&#160;&#176;C (Heidolph Titramax 1000), followed by separation of the plates and analyzation of the acceptor phase by UV-vis plate reader (see at Sect.&#160;<bold><italic toggle="yes">2.6 UV-vis spectroscopy</italic></bold>). Absorbance data of the &#8216;theoretical equilibrium&#8217; was also collected using the so called equilibrium solutions prepared as a mixture of 100 &#181;L acceptor phase solution and 50 &#181;L API solution.</p><p id="Par22">For calculating apparent permeability based on absorbance data, the following equation was used published by Faller et al.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{P}_{a}=-\frac{\text{V}\text{D}\times\:\text{V}\text{A}}{\left(\text{V}\text{D}+\text{V}\text{A}\:\right)\times\:\text{A}\times\:\text{t}}\times\:\text{ln}\left(1-r\right)$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_93425_Article_Equ1.gif"/></alternatives></disp-formula></p><p id="Par23">where <italic toggle="yes">P</italic><sub>a</sub> is the apparent permeability coefficient (cm/s), <italic toggle="yes">V</italic><sub><italic toggle="yes">D</italic></sub> and <italic toggle="yes">V</italic><sub><italic toggle="yes">A</italic></sub> are the volumes in the donor (0.15 cm<sup>3</sup>) and acceptor phase (0.3 cm<sup>3</sup>), <italic toggle="yes">A</italic> is the filter area (0.24 cm<sup>2</sup>), <italic toggle="yes">t</italic> is the incubation time (14400&#160;s) and <inline-formula id="IEq1"><alternatives><tex-math id="M2">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\:r=\frac{\left[\text{A}\text{b}\text{s}\right]\text{A}\text{c}\text{c}\text{e}\text{p}\text{t}\text{o}\text{r}}{\left[\text{A}\text{b}\text{s}\right]\text{E}\text{q}\text{u}\text{l}\text{i}\text{b}\text{r}\text{i}\text{u}\text{m}}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_93425_Article_IEq1.gif"/></alternatives></inline-formula>, where <italic toggle="yes">Abs</italic> is the absorbance of acceptor and equilibrium solutions.</p></sec><sec id="Sec6"><title>Viscosity measurement</title><p id="Par24">Complex viscosity of acceptor phase solutions was measured using an Anton Paar Physica MCR301 (Anton Paar GmbH, Graz, Austria) rheometer in oscillatory mode. Temperature was kept at 35&#8201;&#177;&#8201;0.1&#160;&#176;C by a Peltier device during all measurements. A parallel-plate plate geometry was used with a probe diameter of 25&#160;mm (PP25). In each test, 100 &#181;L of the formulations was introduced on the lower plate, and each formulation was measured in triplicate. Complex viscosity was recorded at a strain (&#947;) of 3% in the angular frequency (&#969;) range of 100&#8201;&#8211;0.1&#160;rad/s with measuring three data points per decade.</p></sec><sec id="Sec7"><title>Zeta potential measurement</title><p id="Par25">Zeta-potential of the acceptor phase solutions was measured using a Malvern Panalitycal ZetaSizer ProBlue instrument equipped with a 633&#160;nm red laser at a detection angle of 173&#176; (back-scattering mode) (Malvern Panalytical Ltd, Malvern, UK). Measurements were performed in 1&#8201;&#215;&#8201;1&#160;cm cuvettes (DTS0012) in triplicates applying a DIP cell (ZEN1002) probe at 35.0&#160;&#176;C. For data analysis ZS Explorer software was used.</p></sec><sec id="Sec8"><title>UV&#8211;Vis spectroscopy</title><p id="Par26">Absorbance data were collected by a Multiskan Sky UV plate reader (ThermoFisher Scientific Inc., Waltham, USA; performance parameters are available in the <bold><italic toggle="yes">Supplementary Material Table S5.</italic></bold>) 150 &#181;L of acceptor and equilibrium solution were placed into the wells of a 96-well UV-Star plate (Greiner Bio-One Hungary Kft, Budapest, Hungary), then the plate was scanned on a wavelength range of 200&#8211;500&#160;nm with 1&#160;nm steps. For permeability calculations, absorbance data measured at the &#955;<sub>max</sub> of each compound was used (limits of detection and quantification are available in the <bold><italic toggle="yes">Supplementary Material Table S4.</italic></bold>).</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par27">Graphpad Prism (v. 8.01) software was used to carry out statistical analysis and to create graphs. Two-way ANOVA test with Dunnett&#8217;s multiple comparisons test was used to determine significant differences at 95% confidence level.</p></sec></sec><sec id="Sec10"><title>Results and discussion</title><sec id="Sec11"><title>Physicochemical characterization of the compound set</title><p id="Par28">For the model development, 27 compounds were selected with various physicochemical properties. Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref>. shows the frequency distribution of molecular weight (MW), lipophilicity (log<italic toggle="yes">P</italic>, log<italic toggle="yes">D</italic><sub>pH7.4</sub>), TPSA and charge state at pH 7.4 of the compounds.</p><p id="Par29">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Frequency distribution of the investigated compounds&#8217; physicochemical properties (<italic toggle="yes">n</italic>&#8201;=&#8201;27). (<bold>A</bold>) Molecular weight, (<bold>B</bold>) lipophilicity, (<bold>C</bold>) topological polar surface area, (<bold>D</bold>) charge state at pH 7.4 and acid-base character (based on p<italic toggle="yes">K</italic><sub>a</sub> values listed in the Supplementary Material, Table <xref rid="MOESM1" ref-type="media">S1</xref>.). All parameters were calculated using the ACD/Percepta software<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e613" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig1_HTML.jpg"/></fig>
</p><p id="Par30">The histograms show the classic range of properties for small molecules according to Lipinski&#8217;s and Veber&#8217;s rules: molecular weight less than 500&#160;g/mol, log<italic toggle="yes">P</italic>/log<italic toggle="yes">D</italic><sub>pH7.4</sub> less than 5, TPSA less than 150 A<sup>2</sup><sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. In this study, the compounds were classified based on their charge states at pH 7.4, considering the possible interaction with negatively charged polymer components (HA, agar) on the acceptor side. The compounds&#8217; frequency distribution exhibits a well-known trend, with the majority of compounds being basic (mostly carrying a positive charge at pH 7.4).</p></sec><sec id="Sec12"><title>Corneal-PAMPA model translation with new analytical method</title><p id="Par31">The corneal-PAMPA method published by our group in 2019 was introduced as a non-cell based model to predict corneal permeability of topically applied drugs<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> and later it was used to build a permeability dataset for developing a new in silico predictive model for corneal permeability<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. In the original setup, HPLC was used as analytical method, but unfortunately, the new setup designed for the posterior segment involves the use of HA which presents some challenges: the removal of HA from a few hundred microliter sample is difficult and wasteful, while not removing it could potentially cause damage to the instrument due to the pH-sensitive viscosity of HA<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. To solve this problem, UV-vis plate reader (as a direct HTS analysis without sample preparation steps) was applied, and therefore a new calculation method was required to gain permeability data due to the lower sensitivity of this instrumentation. <italic toggle="yes">Faller et al.</italic> published a PAMPA method supported by an UV-vis plate reader, which involves a simpler equation to calculate apparent permeability (<italic toggle="yes">P</italic><sub>a,</sub> Eq.&#160;(<xref rid="Equ1" ref-type="disp-formula">1</xref>)). In this case only the absorbance data from the acceptor phase and the theoretical equilibrium (initial donor and acceptor solution mixed in 1:2 ratio) is to be collected.</p><p id="Par32">To demonstrate the applicability of the new analytical and calculating method, 19 molecules were measured with the modified corneal-PAMPA method using higher drug solution concentrations (250 &#181;M) due to the new method&#8217;s lower sensitivity (UV-vis plate reader). As shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>., newly obtained permeability values (<italic toggle="yes">P</italic><sub>a, PAMPA&#8722;UV</sub>) exhibited a strong correlation with the values obtained from prior corneal-PAMPA measurements using HPLC (<italic toggle="yes">P</italic><sub>e, PAMPA&#8722;HPLC</sub>, R<sup>2</sup>&#8201;=&#8201;0.903).</p><p id="Par33">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Corneal-PAMPA model translation (<italic toggle="yes">n</italic>&#8201;=&#8201;19)&#8212;linear correlation between permeability values obtained from the original corneal-PAMPA (abscissa) and the newly introduced modified PAMPA model (ordinate).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e686" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig2_HTML.jpg"/></fig>
</p><p id="Par34">Based on this, the corneal-PAMPA method was successfully translated to the new analytical method required further on for detection of drugs in the HA-containing media.</p></sec><sec id="Sec13"><title>Development of the Vitreous-PAMPA model</title><p id="Par35">For developing a novel permeability model, the acceptor medium was systematically modified to mimic the VH. Meanwhile, general trends were observed regardless the acceptor medium, as neutral and positively charged APIs typically exhibited higher permeability compared to zwitterionic and negatively charged ones (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>.).</p><p id="Par36">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Box plot of compounds&#8217; permeability in the models based on charge state (<italic toggle="yes">n</italic>&#8201;=&#8201;27).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e709" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig3_HTML.jpg"/></fig>
</p><p id="Par37">It is probable that the stable trends arise from the constant membrane composition (phosphatidylcholine in all cases), which is a crucial model parameter in PAMPA. Most cases eventually showed detectable (low to moderate) shifts in permeability. Henceforth, the focus is on the direction and magnitude of shifts rather than precise permeability values (details are available in the <bold><italic toggle="yes">Supplementary Material</italic></bold>,<bold><italic toggle="yes"> in Figure </italic></bold><xref rid="MOESM1" ref-type="media"><bold><italic toggle="yes">S1</italic></bold></xref><bold><italic toggle="yes">.</italic></bold>).</p><sec id="Sec14"><title>Permeability of compounds using HA on the acceptor side</title><p id="Par38">In the first step, HA was added to the corneal-PAMPA model as acceptor-phase component. Two types of Na-HA were used in the experiments at 0.1 w/v% concentration: mid molecular weight (200&#160;kDa, HA-200) and high molecular weight HA (855&#160;kDa, HA-855). Compared to the corneal-PAMPA model translation, 4 APIs had to be removed from the experiment as they could not be detected in the acceptor medium (due to very low permeability and the interference of HA with their absorbance signal: dexamethasone, enoxacin, propamidine, ranitidine). The remaining set was expanded with an additional 12 compounds and compared to the permeability values measured with the corneal-PAMPA model (<italic toggle="yes">n</italic>&#8201;=&#8201;27). According to two-way ANOVA followed by Dunnett&#8217;s post hoc test, the presence of HA (regardless of molecular weight) did not affect the permeability values significantly in most cases compared to the corneal-PAMPA (PBS as acceptor media) permeability (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>. and Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>.; ANOVA results can be found in the <bold><italic toggle="yes">Supplementary Material</italic></bold>,<bold><italic toggle="yes"> Table S2.</italic></bold>). In six unique cases for HA-200, and for two cases for HA-855 a significant increase, meanwhile in three and two cases a significant decrease in permeability was measured respectively. Permeability increases in these cases were mostly associated with neutral compounds, while slight decrease was observed for a few basic compounds.</p><p id="Par39">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Permeability differences with 95% confidence intervals against corneal-PAMPA (PBS) vs. HA-200 (0.1 w/v%) as acceptor medium. Significant differences (two-way ANOVA, Dunnett&#8217;s multiple comparisons test, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, <italic toggle="yes">n</italic>&#8201;&#8805;&#8201;3) are marked with red (decrease) and green (increase) arrows.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e758" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig4_HTML.jpg"/></fig>
</p><p id="Par40">It is known that drugs applied topically on the eye cannot reach the VH in the same extent as they reach the aqueous humor<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Considering this, a model predicting significantly lower permeability compared to the corneal-PAMPA (which models the penetration toward the aqueous humor) would be more realistic.</p><p id="Par41">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Permeability differences with 95% confidence intervals against corneal-PAMPA (PBS) vs. HA-855 (0.1 w/v%) as acceptor medium. Significant differences (two-way ANOVA, Dunnett&#8217;s multiple comparisons test, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, <italic toggle="yes">n</italic>&#8201;&#8805;&#8201;3) are marked with red (decrease) and green(increase) arrows.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e781" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec15"><title>Permeability of compounds with HA and agar on the acceptor side</title><p id="Par42">In 2020, <italic toggle="yes">Thakur et al.</italic> published a paper about HA and agar-based hydrogels as suitable VH mimetics for in vitro drug and particle migration evaluations<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. In their study three types of HA-agar hydrogels were investigated with various HA and agar content from rheological and particle migration aspects. Hyaluronate as a viscoelastic polymer is an essential part of the model (as a native component of the VH itself) while agar is used to achieve elasticity and so to mimic the properties of the naturally occurring collagen fibrils<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. As a result of their study, they found the hydrogel containing 0.7&#160;mg/ml (0.07 w/v%) HA (high molecular weight) and 0.95&#160;mg/ml (0.095 w/v%) agar to be the most similar to bovine VH in the above-mentioned experiments. Since they conducted no permeability measurements with this promising hydrogel, we tested it as an acceptor medium in the PAMPA measurements. To gain further insight, experiments using only agar-containing acceptor phase were also carried out, since the standalone effect of the high molecular weight Na-HA was already investigated.</p><p id="Par43">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Permeability differences with 95% confidence intervals against corneal-PAMPA (PBS) vs. HA-855&#8201;+&#8201;agar (HA:0.07 w/v%; agar: 0.095 w/v%) as acceptor medium. Significant differences (two-way ANOVA, Dunnett&#8217;s multiple comparisons test, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, <italic toggle="yes">n</italic>&#8201;&#8805;&#8201;3) are marked with red (decrease) and green (increase) arrows. Compounds with p<inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\approx\:$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_93425_Article_IEq2.gif"/></alternatives></inline-formula>0.05 are marked with red asterisks. Details on statistical analysis can be found in the Supplementary Material, Table S2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e819" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig6_HTML.jpg"/></fig>
</p><p id="Par44">As the results show, introduction of agar to the system significantly decreased the permeability of nearly all drugs with positive charge (~&#8201;bases) meanwhile, for other charge categories only small differences could be obtained (significant increase for hydrocortisone and diclofenac) (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>.). On the other hand, in the case of agar model, significant increase had not been observed for any compounds, moreover, two anionic compounds showed significant decrease in permeability (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>.). In general, the permeability values of negative and zwitterionic compounds are lower, therefore smaller differences can be recognized as significant ones. Nevertheless, examination of the figures reveals that the position of the negatively charged and zwitterionic datapoints were not changed that much (perhaps approaching the threshold of statistical traceability). In summary for cationic compounds, HA-855&#8201;+&#8201;agar could decrease the permeability in a greater extent than agar alone (chloroquine, diltiazem, duloxetine, methapyrilene, oxybuprocaine, propranolol, pyrilamine, tetracaine, timolol).</p><p id="Par45">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Permeability differences with 95% confidence intervals against corneal-PAMPA (PBS) vs. agar (0.095 w/v%) as acceptor medium. Significant differences (two-way ANOVA, Dunnett&#8217;s multiple comparisons test, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, <italic toggle="yes">n</italic>&#8201;&#8805;&#8201;3) are marked with red (decrease) and green (increase) arrows. Compounds with p<inline-formula id="IEq3"><alternatives><tex-math id="M4">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\approx\:$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_93425_Article_IEq3.gif"/></alternatives></inline-formula>0.05 are marked with red asterisks. Details on statistical analysis can be found in the Supplementary Material, Table S2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e850" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig7_HTML.jpg"/></fig>
</p><p id="Par46">According to a simple one-way ANOVA analysis followed by Dunnett&#8217;s post-hoc test, only HA-855&#8201;+&#8201;agar and agar models showed significant differences (**, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) in permeability, compared to PBS (See <bold><italic toggle="yes">Supplementary Material</italic></bold>,<bold><italic toggle="yes"> Table S3.</italic></bold>)</p></sec></sec><sec id="Sec16"><title>PAMPA with Porcine vitreous humor</title><p id="Par47">There has been an attempt made to use freshly excised porcine vitreous as acceptor medium in the experiments, for three APIs with sufficient absorption at a wavelength closer to the visible range (~&#8201;300&#160;nm) considering the cut-off of VH. Beyond the issue of inhomogeneous VH samples (hence the inaccuracies in pipetting) no significant signal (or non-noise signal indicating the presence of an API) could be found in the acceptor wells, which could be the result of the high UV absorption of the VH itself. When preparing the equilibrium solutions, one unit of API solution (250 &#181;M, PBS) was mixed with (approximately) two units of VH. Figure&#160;<xref rid="Fig8" ref-type="fig">8</xref><bold>/A-C.</bold> shows the spectra of the mixed samples along with the individual spectra of the APIs. Two APIs (ketorolac, moxifloxacin) absorption peaks could be observed, at 341 and 320&#160;nm respectively, however these components are characterized with low permeability due to their acidic/amphoteric properties, therefore their possible absence on the acceptor side is reasonable. To gain clear spectra by removing background components, precipitation was attempted using cold acetonitrile, centrifugation, and filtration. However, no APIs could be detected in the filtered material, possibly due to the detection limit or their loss along with some protein components during the process. The sample preparation process of VH containing samples was not further improved or investigated in this study.</p><p id="Par48">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>UV spectra of the equilibrium solutions (containing VH) vs. the initial API solutions (oxybuprocaine&#8212;<bold>A</bold>, moxifloxacin&#8212;<bold>B</bold>, ketorolac&#8212;<bold>C</bold>), and spectra of the various acceptor media (<bold>D</bold>). After removing protein components by precipitation and filtering, no API could be detected.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e893" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig8_HTML.jpg"/></fig>
</p><p id="Par49">As Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>/D. shows, the background absorbance of the HA-agar medium is negligible compared to the VH, therefore it is a more suitable medium for rapid, spectroscopic detection of APIs.</p></sec><sec id="Sec17"><title>Physicochemical characterization of the acceptor media</title><p id="Par50">To further characterize the acceptor media and to reveal possible phenomena possibly responsible for the changes in permeability, the solutions&#8217; complex viscosity and zeta potential were measured and compared with those of freshly excised VH samples of porcine origin.</p><p id="Par51">Acceptor media was characterized using a rheometer in oscillatory mode. Complex viscosity of the samples was plotted as the function of angular frequency in Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>. On the plot, two groups came apart: PBS and HA solutions showed low complex viscosity meanwhile HA-855&#8201;+&#8201;agar and agar-containing samples were found to be similar to the porcine VH, showing higher complex viscosities at low shear rates and a gradual decrease with the increasing shear rate.</p><p id="Par52">
<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Complex viscosity of solutions used as acceptor media against angular frequency at 35&#160;&#176;C.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e917" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig9_HTML.jpg"/></fig>
</p><p id="Par53">Complex viscosity values obtained at 10&#160;rad/s were further compared in Fig.&#160;<xref rid="Fig10" ref-type="fig">10</xref>., where except from HA-855&#8201;+&#8201;agar, all samples showed significantly different complex viscosity compared to the VH. The values obtained for HA-855&#8201;+&#8201;agar sample were similar to that reported by <italic toggle="yes">Thakur et al.</italic>., additionally, the porcine VH also displayed comparable viscosity to their bovine sample.</p><p id="Par54">
<fig id="Fig10" position="float" orientation="portrait"><label>Fig. 10</label><caption><p>Complex viscosity of the solutions used as acceptor media at an angular frequency of 10&#160;rad/s at 35&#160;&#176;C. Significant differences compared to the vitreous humor were revealed using one-way ANOVA with Dunnett&#8217;s multiple comparisons test and are marked with asterisks (**: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e942" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig10_HTML.jpg"/></fig>
</p><sec id="Sec18"><title>Zeta potential measurement</title><p id="Par55">Measuring zeta potential of polymer solutions can be helpful in the understanding of molecular interactions in aqueous medium. Zeta potentials of HA-containing solutions were found to be around &#8722;&#8201;20 mV, while HA-855&#8201;+&#8201;agar and the VH itself showed much lower zeta potential (~ -10 mV). In fact, agar showed the second lowest zeta potential (~ -5 mV) as PBS hardly differed from zero, since particles are not present in this medium (Fig.&#160;<xref rid="Fig11" ref-type="fig">11</xref>.). According to the results, HA-855&#8201;+&#8201;agar closely resembled porcine VH, possibly indicating similar electrolyte content and molecular interactions in solutions. Hyaluronates and agar are known to carry negative charges in solutions, moreover, the vitreous humor itself have been described as a negatively charged meshwork<sup><xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref></sup>. Studies on the migration of charged nanoparticles through the vitreous body revealed that anionic particles may freely diffuse through it, meanwhile cationic particles are trapped inside, regardless of their size [113, 117]. The fact, that in our case polymeric samples without agar showed higher negative zeta potentials suggests that other interactions may exist that influence the permeability of compounds in agar-containing models, apart from electrostatic ones.</p><p id="Par56">
<fig id="Fig11" position="float" orientation="portrait"><label>Fig. 11</label><caption><p>Zeta potential of various solutions used as acceptor media at 35&#160;&#176;C. Significant differences compared to the vitreous humor were revealed using one-way ANOVA with Dunnett&#8217;s multiple comparisons test and are marked with asterisks (****: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001); n.m: not measurable.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e970" position="float" orientation="portrait" xlink:href="41598_2025_93425_Fig11_HTML.jpg"/></fig>
</p><p id="Par57">In summary, a model based on corneal-PAMPA with modified acceptor medium (HA and agar containing solution) offers a promising approach for predicting the permeability of drugs toward the vitreous after topical administration. This is supported by findings indicating similarity in zeta potential and rheological behaviour to porcine vitreous humor, as well as consistent effects observed for charged molecules, aligning with previous reports. However, it&#8217;s essential to note that establishing a well-defined model would require proper validation, which is currently hindered by the limited availability of data on the vitreous-directed permeability of APIs.</p></sec></sec></sec><sec id="Sec19"><title>Conclusion</title><p id="Par58">As a prelude of this work, <italic toggle="yes">Thakur et al.</italic> validated a Na-HA and agar containing hydrogel as suitable substitute of vitreous humor, possessing similar rheological properties, and allowing similar particle migration in this medium. In this study, the same hydrogel was tested in the in vitro PAMPA model as acceptor medium, and as a result, significantly lower permeability could be obtained compared to the corneal-PAMPA model, or the modified, HA-containing models. Further investigations revealed that this hydrogel can in fact be a good analogue to the vitreous body, as zeta potentials of this media and porcine vitreous body were found quite the same, which shows similar behaviour of their molecules in the solution phase.</p><p id="Par59">The current model for posterior segment permeability may not be optimal due to the limited data available on the actual permeability of topically applied drugs toward the posterior segment. This lack of data hinders the ability to assess the similarity or validate the modell adequately. However, without improved predictive and high-throughput models, and considering the challenges of directly obtaining information from animal vitreous studies, this model could serve as the initial step toward predicting the posterior segment permeability of drugs applied topically on the eye without the involvement of laboratory animals.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_93425_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>APIs</term><def><p id="Par3">Active pharmaceutical ingredients</p></def></def-item><def-item><term>HA</term><def><p id="Par4">Hyaluronate</p></def></def-item><def-item><term>HA-200</term><def><p id="Par5">Hyaluronate with molecular weight of 200&#160;kDa</p></def></def-item><def-item><term>HA-855</term><def><p id="Par6">Hyaluronate with molecular weight of 855&#160;kDa</p></def></def-item><def-item><term>HPLC</term><def><p id="Par7">Hight performance liquid chromatography</p></def></def-item><def-item><term>MW</term><def><p id="Par8">Molecular weight</p></def></def-item><def-item><term>Na-HA</term><def><p id="Par9">Sodium hyaluronate</p></def></def-item><def-item><term>PAMPA</term><def><p id="Par10">Parallel artificial membrane permeability assay</p></def></def-item><def-item><term>PBS</term><def><p id="Par11">Phosphate buffered saline</p></def></def-item><def-item><term>PC</term><def><p id="Par12">Phosphatidylcholine</p></def></def-item><def-item><term>TPSA</term><def><p id="Par13">Topological polar surface area</p></def></def-item><def-item><term>VH</term><def><p id="Par14">Vitreous humor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We acknowledge Erika Forrai for her suggestions made regarding hyaluronate solutions, and the co-workers of Porci&#243;-&#201;K Ltd. for the fresh porcine eyes. A. Vincze acknowledges the Richter Gedeon Excellence PhD Scholarship of Richter Gedeon Foundation.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Anna Vincze: Writing - Original draft preparation, Investigation, Formal Analysis, Visualization, Eszter Simon: Investigation, G&#225;bor Kopl&#225;nyi: Methodology, Investigation, J&#243;zsef Gergely Stankovits: Methodology, Writing - Review &amp; Editing, Di&#225;na Balogh-Weiser: Methodology, Writing - Review &amp; Editing, Benj&#225;min Gyarmati: Methodology, Writing - Review &amp; Editing, Zolt&#225;n Zsolt Nagy: Methodology, Resources, Gy&#246;rgy T. Balogh: Conceptualization, Supervision, Writing - Review &amp; Editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Semmelweis University.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data is available in the Supplementary Material.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>PM</given-names></name><name name-style="western"><surname>Olejnik</surname><given-names>O</given-names></name><name name-style="western"><surname>Chang-Lin</surname><given-names>JE</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>CG</given-names></name></person-group><article-title>Topical and systemic drug delivery to the posterior segments</article-title><source>Adv. Drug Deliv. Rev.</source><year>2005</year><volume>57</volume><fpage>2010</fpage><lpage>2032</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2005.09.004</pub-id><pub-id pub-id-type="pmid">16289435</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Hughes, P. M., Olejnik, O., Chang-Lin, J. E. &amp; Wilson, C. G. Topical and systemic drug delivery to the posterior segments. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>57</bold>, 2010&#8211;2032. 10.1016/j.addr.2005.09.004 (2005). 14 SPEC. ISS.<pub-id pub-id-type="pmid">16289435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2005.09.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">L&#246;scher, M., Seiz, C., Hurst, J. &amp; Schnichels, S. Topical drug delivery to the posterior segment of the eye. <italic toggle="yes">Pharmaceutics</italic><bold>14</bold> (1). 10.3390/pharmaceutics14010134 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14010134</pub-id><pub-id pub-id-type="pmcid">PMC8779621</pub-id><pub-id pub-id-type="pmid">35057030</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barar</surname><given-names>J</given-names></name><name name-style="western"><surname>Javadzadeh</surname><given-names>AR</given-names></name><name name-style="western"><surname>Omidi</surname><given-names>Y</given-names></name></person-group><article-title>Ocular novel drug delivery: impacts of membranes and barriers</article-title><source>Expert Opin. Drug Deliv.</source><year>2008</year><volume>5</volume><issue>5</issue><fpage>567</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1517/17425247.5.5.567</pub-id><pub-id pub-id-type="pmid">18491982</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Barar, J., Javadzadeh, A. R. &amp; Omidi, Y. Ocular novel drug delivery: impacts of membranes and barriers. <italic toggle="yes">Expert Opin. Drug Deliv.</italic><bold>5</bold> (5), 567&#8211;581. 10.1517/17425247.5.5.567 (2008).<pub-id pub-id-type="pmid">18491982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425247.5.5.567</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moisseiev</surname><given-names>E</given-names></name><name name-style="western"><surname>Loewenstein</surname><given-names>A</given-names></name></person-group><article-title>Drug delivery to the posterior segment of the eye</article-title><source>Dev. Ophthalmol.</source><year>2017</year><volume>58</volume><fpage>87</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1159/000455276</pub-id><pub-id pub-id-type="pmid">28351054</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Moisseiev, E. &amp; Loewenstein, A. Drug delivery to the posterior segment of the eye. <italic toggle="yes">Dev. Ophthalmol.</italic><bold>58</bold>, 87&#8211;101. 10.1159/000455276 (2017).<pub-id pub-id-type="pmid">28351054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000455276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>SS</given-names></name><name name-style="western"><surname>Denham</surname><given-names>LV</given-names></name><name name-style="western"><surname>Elison</surname><given-names>JR</given-names></name></person-group><article-title>Drug delivery to the posterior segment of the eye for Pharmacologic therapy</article-title><source>Expert Rev. Ophthalmol.</source><year>2010</year><volume>5</volume><issue>1</issue><fpage>75</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1159/000455276</pub-id><pub-id pub-id-type="pmid">20305803</pub-id><pub-id pub-id-type="pmcid">PMC2839363</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Shah, S. S., Denham, L. V. &amp; Elison, J. R. Drug delivery to the posterior segment of the eye for Pharmacologic therapy. <italic toggle="yes">Expert Rev. Ophthalmol.</italic><bold>5</bold> (1), 75&#8211;93. 10.1159/000455276 (2010).<pub-id pub-id-type="pmid">20305803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/eop.09.70</pub-id><pub-id pub-id-type="pmcid">PMC2839363</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of dorzolamide hydrochloride on ocular tissues</article-title><source>J. Ocul. Pharmacol. Ther.</source><year>2004</year><volume>20</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1089/108076804772745419</pub-id><pub-id pub-id-type="pmid">15006154</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Inoue, J. et al. Effects of dorzolamide hydrochloride on ocular tissues. <italic toggle="yes">J. Ocul. Pharmacol. Ther.</italic><bold>20</bold> (1), 1&#8211;13. 10.1089/108076804772745419 (2004).<pub-id pub-id-type="pmid">15006154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/108076804772745419</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acheampong</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes</article-title><source>Drug Metab. Dispos.</source><year>2002</year><volume>30</volume><issue>4</issue><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1124/dmd.30.4.421</pub-id><pub-id pub-id-type="pmid">11901096</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Acheampong, A. A. et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. <italic toggle="yes">Drug Metab. Dispos.</italic><bold>30</bold> (4), 421&#8211;429. 10.1124/dmd.30.4.421 (2002).<pub-id pub-id-type="pmid">11901096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.30.4.421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holl&#243;</surname><given-names>G</given-names></name><etal/></person-group><article-title>Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration</article-title><source>Invest. Ophthalmol. Visual Sci.</source><year>2006</year><volume>47</volume><issue>1</issue><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1167/iovs.05-0945</pub-id><pub-id pub-id-type="pmid">16384968</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Holl&#243;, G. et al. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. <italic toggle="yes">Invest. Ophthalmol. Visual Sci.</italic><bold>47</bold> (1), 235&#8211;240. 10.1167/iovs.05-0945 (2006).<pub-id pub-id-type="pmid">16384968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.05-0945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Lin, C. W. et al. Discovery and preclinical development of Netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. <italic toggle="yes">J. Ocul. Pharmacol. Ther.</italic><bold>34</bold>, 1&#8211;2. 10.1089/jop.2017.0023 (Jan. 2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jop.2017.0023</pub-id><pub-id pub-id-type="pmcid">PMC5963640</pub-id><pub-id pub-id-type="pmid">28609185</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koeberle</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>PM</given-names></name><name name-style="western"><surname>Skellern</surname><given-names>GG</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>CG</given-names></name></person-group><article-title>Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye</article-title><source>Pharm. Res.</source><year>2006</year><volume>23</volume><issue>12</issue><fpage>2781</fpage><lpage>2798</lpage><pub-id pub-id-type="doi">10.1007/s11095-006-9106-2</pub-id><pub-id pub-id-type="pmid">17103338</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Koeberle, M. J., Hughes, P. M., Skellern, G. G. &amp; Wilson, C. G. Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye. <italic toggle="yes">Pharm. Res.</italic><bold>23</bold> (12), 2781&#8211;2798. 10.1007/s11095-006-9106-2 (2006).<pub-id pub-id-type="pmid">17103338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-006-9106-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Davis, B. M. et al. Apr., Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5-associated Liposomes, <italic toggle="yes">Small</italic>, vol. 10, no. 8, pp. 1575&#8211;1584, (2014). 10.1002/SMLL.201303433<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201303433</pub-id><pub-id pub-id-type="pmid">24596245</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Balguri, S. P., Adelli, G. R. &amp; Majumdar, S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues, <italic toggle="yes">European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</italic>, vol. 109, pp. 224&#8211;235, Dec. (2016). 10.1016/J.EJPB.2016.10.015<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2016.10.015</pub-id><pub-id pub-id-type="pmcid">PMC5345266</pub-id><pub-id pub-id-type="pmid">27793755</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Schnichels, S. et al. Mar., Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles, <italic toggle="yes">ACS applied materials &amp; interfaces</italic>, vol. 13, no. 8, pp. 9445&#8211;9456, (2021). 10.1021/ACSAMI.0C18626<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.0c18626</pub-id><pub-id pub-id-type="pmid">33528240</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Johannsdottir, S. et al. Jun., Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits, <italic toggle="yes">Journal of Drug Delivery Science and Technology</italic>, vol. 45, pp. 449&#8211;454, (2018). 10.1016/J.JDDST.2018.04.007</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Xu, X., Sun, L., Zhou, L., Cheng, Y. &amp; Cao, F. Functional Chitosan oligosaccharide nanomicelles for topical ocular drug delivery of dexamethasone. <italic toggle="yes">Carbohydr. Polym.</italic><bold>227</bold>, 115356. 10.1016/J.CARBPOL.2019.115356 (Jan. 2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carbpol.2019.115356</pub-id><pub-id pub-id-type="pmid">31590850</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye</article-title><source>Drug Deliv.</source><year>2019</year><volume>26</volume><issue>1</issue><fpage>188</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1080/10717544.2019.1571122</pub-id><pub-id pub-id-type="pmid">30835587</pub-id><pub-id pub-id-type="pmcid">PMC6407580</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Li, J. et al. A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye. <italic toggle="yes">Drug Deliv.</italic><bold>26</bold> (1), 188&#8211;198. 10.1080/10717544.2019.1571122 (2019).<pub-id pub-id-type="pmid">30835587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10717544.2019.1571122</pub-id><pub-id pub-id-type="pmcid">PMC6407580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waga</surname><given-names>J</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>A</given-names></name><name name-style="western"><surname>Ehinger</surname><given-names>B</given-names></name></person-group><article-title>Intraocular Microdialysis with permanently implanted probes in rabbit</article-title><source>Acta Ophthalmol.</source><year>1991</year><volume>69</volume><issue>5</issue><fpage>618</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1111/j.1755-3768.1991.tb04849.x</pub-id><pub-id pub-id-type="pmid">1776415</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Waga, J., Ohta, A. &amp; Ehinger, B. Intraocular Microdialysis with permanently implanted probes in rabbit. <italic toggle="yes">Acta Ophthalmol.</italic><bold>69</bold> (5), 618&#8211;624. 10.1111/j.1755-3768.1991.tb04849.x (1991).<pub-id pub-id-type="pmid">1776415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-3768.1991.tb04849.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stempels</surname><given-names>N</given-names></name><name name-style="western"><surname>Tassignon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sarre</surname><given-names>S</given-names></name></person-group><article-title>A removable ocular Microdialysis system for measuring vitreous biogenic amines</article-title><source>Graefe&#8217;s Archive Clin. Experimental Ophthalmol.</source><year>1993</year><volume>231</volume><issue>11</issue><fpage>651</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1007/BF00921960</pub-id><pub-id pub-id-type="pmid">8258400</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Stempels, N., Tassignon, M. J. &amp; Sarre, S. A removable ocular Microdialysis system for measuring vitreous biogenic amines. <italic toggle="yes">Graefe&#8217;s Archive Clin. Experimental Ophthalmol.</italic><bold>231</bold> (11), 651&#8211;655. 10.1007/BF00921960 (1993).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00921960</pub-id><pub-id pub-id-type="pmid">8258400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Prieto, E. et al. Dexamethasone delivery to the ocular posterior segment by sustained-release laponite formulation. <italic toggle="yes">Biomedical Mater. (Bristol)</italic>. <bold>15</bold> (6). 10.1088/1748-605X/aba445 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/1748-605X/aba445</pub-id><pub-id pub-id-type="pmid">32647098</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Maurice, D. M. Drug delivery to the posterior segment from drops, <italic toggle="yes">Survey of Ophthalmology</italic>, vol. 47, no. 4 SUPPL. 1, (2002). 10.1016/S0039-6257(02)00326-0<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0039-6257(02)00326-0</pub-id><pub-id pub-id-type="pmid">12204700</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shelley</surname><given-names>H</given-names></name><name name-style="western"><surname>Rodriguez-Galarza</surname><given-names>RM</given-names></name><name name-style="western"><surname>Duran</surname><given-names>SH</given-names></name><name name-style="western"><surname>Abarca</surname><given-names>EM</given-names></name><name name-style="western"><surname>Babu</surname><given-names>RJ</given-names></name></person-group><article-title>In situ gel formulation for enhanced ocular delivery of Nepafenac</article-title><source>J. Pharm. Sci.</source><year>2018</year><volume>107</volume><issue>12</issue><fpage>3089</fpage><lpage>3097</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.08.013</pub-id><pub-id pub-id-type="pmid">30170009</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Shelley, H., Rodriguez-Galarza, R. M., Duran, S. H., Abarca, E. M. &amp; Babu, R. J. In situ gel formulation for enhanced ocular delivery of Nepafenac. <italic toggle="yes">J. Pharm. Sci.</italic><bold>107</bold> (12), 3089&#8211;3097. 10.1016/j.xphs.2018.08.013 (2018).<pub-id pub-id-type="pmid">30170009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2018.08.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Loch, C., Nagel, S., Guthoff, R., Seidlitz, A. &amp; Weitschies, W. The vitreous model - A new in vitro test method simulating the vitreous body, <italic toggle="yes">Biomedizinische Technik</italic>, vol. 57, no. SUPPL. 1 TRACK-O, pp. 281&#8211;284, (2012). 10.1515/bmt-2012-4106<pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/bmt-2012-4106</pub-id><pub-id pub-id-type="pmid">23096337</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Henein, C. et al. Hydrodynamics of intravitreal injections into liquid vitreous substitutes, <italic toggle="yes">Pharmaceutics</italic>, vol. 11, no. 8, pp. 1&#8211;19, (2019). 10.3390/pharmaceutics11080371<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics11080371</pub-id><pub-id pub-id-type="pmcid">PMC6723562</pub-id><pub-id pub-id-type="pmid">31374925</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">M. P. Kummer, J. J. Abbott, S. Dinser, and B. J. Nelson, Artificial vitreous humor for in vitro experiments., Conference proceedings: &#8230; Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society.Conference, pp. 6407&#8211;6410, 2007.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/IEMBS.2007.4353822</pub-id><pub-id pub-id-type="pmid">18003488</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awwad</surname><given-names>S</given-names></name><name name-style="western"><surname>Lockwood</surname><given-names>A</given-names></name><name name-style="western"><surname>Brocchini</surname><given-names>S</given-names></name><name name-style="western"><surname>Khaw</surname><given-names>PT</given-names></name></person-group><article-title>The PK-Eye: A novel in vitro ocular flow model for use in preclinical drug development</article-title><source>J. Pharm. Sci.</source><year>2015</year><volume>104</volume><issue>10</issue><fpage>3330</fpage><lpage>3342</lpage><pub-id pub-id-type="doi">10.1002/jps.24480</pub-id><pub-id pub-id-type="pmid">26108574</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Awwad, S., Lockwood, A., Brocchini, S. &amp; Khaw, P. T. The PK-Eye: A novel in vitro ocular flow model for use in preclinical drug development. <italic toggle="yes">J. Pharm. Sci.</italic><bold>104</bold> (10), 3330&#8211;3342. 10.1002/jps.24480 (2015).<pub-id pub-id-type="pmid">26108574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.24480</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Darg&#243;, G. et al. Corneal-PAMPA: A novel, non-cell-based assay for prediction of corneal drug permeability, <italic toggle="yes">European Journal of Pharmaceutical Sciences</italic>, vol. 128, no. December pp. 232&#8211;239, 2019, (2018). 10.1016/j.ejps.2018.12.012<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2018.12.012</pub-id><pub-id pub-id-type="pmid">30553815</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wohnsland</surname><given-names>F</given-names></name><name name-style="western"><surname>Faller</surname><given-names>B</given-names></name></person-group><article-title>High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes</article-title><source>J. Med. Chem.</source><year>2001</year><volume>44</volume><issue>6</issue><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1021/jm001020e</pub-id><pub-id pub-id-type="pmid">11300874</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Wohnsland, F. &amp; Faller, B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. <italic toggle="yes">J. Med. Chem.</italic><bold>44</bold> (6), 923&#8211;930. 10.1021/jm001020e (2001).<pub-id pub-id-type="pmid">11300874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm001020e</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">ACD/Labs Percepta, version: 2019.1.0; Accessed: Sep 04, 2024, (2020). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acdlabs.com/products/percepta/">https://www.acdlabs.com/products/percepta/</ext-link>. <italic toggle="yes">Advanced Chemistry Development, Inc., Toronto, Canada</italic>: 2019.1.0.</mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Lipinski, C. A., Lombardo, F., Dominy, B. W. &amp; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, <bold>46</bold>, pp. 3&#8211;26, (2001).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(00)00129-0</pub-id><pub-id pub-id-type="pmid">11259830</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates, pp. 2615&#8211;2623, (2002).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm020017n</pub-id><pub-id pub-id-type="pmid">12036371</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Vincze, A., Darg&#243;, G., R&#225;cz, A. &amp; Balogh, G. T. A corneal-PAMPA-based in Silico model for predicting corneal permeability. <italic toggle="yes">J. Pharm. Biomed. Anal.</italic><bold>203</bold>10.1016/j.jpba.2021.114218 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpba.2021.114218</pub-id><pub-id pub-id-type="pmid">34166924</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatej</surname><given-names>I</given-names></name><name name-style="western"><surname>Popa</surname><given-names>M</given-names></name><name name-style="western"><surname>Rinaudo</surname><given-names>M</given-names></name></person-group><article-title>Role of the pH on hyaluronan behavior in aqueous solution</article-title><source>Biomacromolecules</source><year>2005</year><volume>6</volume><issue>1</issue><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1021/bm040050m</pub-id><pub-id pub-id-type="pmid">15638505</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Gatej, I., Popa, M. &amp; Rinaudo, M. Role of the pH on hyaluronan behavior in aqueous solution. <italic toggle="yes">Biomacromolecules</italic><bold>6</bold> (1), 61&#8211;67. 10.1021/bm040050m (2005).<pub-id pub-id-type="pmid">15638505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bm040050m</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>SS</given-names></name><name name-style="western"><surname>Shenoy</surname><given-names>SK</given-names></name><name name-style="western"><surname>Suk</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>JS</given-names></name><name name-style="western"><surname>Rupenthal</surname><given-names>ID</given-names></name></person-group><article-title>Validation of hyaluronic acid-agar-based hydrogels as vitreous humor mimetics for in vitro drug and particle migration evaluations</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2020</year><volume>148</volume><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2020.01.008</pub-id><pub-id pub-id-type="pmid">31981693</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Thakur, S. S., Shenoy, S. K., Suk, J. S., Hanes, J. S. &amp; Rupenthal, I. D. Validation of hyaluronic acid-agar-based hydrogels as vitreous humor mimetics for in vitro drug and particle migration evaluations. <italic toggle="yes">Eur. J. Pharm. Biopharm.</italic><bold>148</bold>, 118&#8211;125. 10.1016/j.ejpb.2020.01.008 (2020).<pub-id pub-id-type="pmid">31981693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2020.01.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Heys</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Barocas</surname><given-names>VH</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>TW</given-names></name></person-group><article-title>Permeability and diffusion in vitreous humor: implications for drug delivery</article-title><source>Pharm. Res.</source><year>2000</year><volume>17</volume><issue>6</issue><fpage>664</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1023/A:1007517912927</pub-id><pub-id pub-id-type="pmid">10955838</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Xu, J., Heys, J. J., Barocas, V. H. &amp; Randolph, T. W. Permeability and diffusion in vitreous humor: implications for drug delivery. <italic toggle="yes">Pharm. Res.</italic><bold>17</bold> (6), 664&#8211;669. 10.1023/A:1007517912927 (2000).<pub-id pub-id-type="pmid">10955838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1007517912927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Litt</surname><given-names>M</given-names></name><name name-style="western"><surname>Buchsbaum</surname><given-names>G</given-names></name></person-group><article-title>Rheology of the vitreous body: part 3. Concentration of electrolytes, collagen and hyaluronic acid</article-title><source>Biorheology</source><year>1994</year><volume>31</volume><issue>4</issue><fpage>339</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.3233/BIR-1994-31404</pub-id><pub-id pub-id-type="pmid">7981434</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Lee, B., Litt, M. &amp; Buchsbaum, G. Rheology of the vitreous body: part 3. Concentration of electrolytes, collagen and hyaluronic acid. <italic toggle="yes">Biorheology</italic><bold>31</bold> (4), 339&#8211;351. 10.3233/BIR-1994-31404 (1994).<pub-id pub-id-type="pmid">7981434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/bir-1994-31404</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">AgarGel &amp; Corporation Properties of agar-agar /<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.agargel.com.br/agar.html/">http://www.agargel.com.br/agar.html/</ext-link>. Accessed on Feb 2, 2024.</mixed-citation></ref></ref-list></back></article></pmc-articleset>